Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)
Status:
Recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
1. To compare systemic neoadjuvant therapy (combination of immune checkpoint inhibitors and
anti-angiogenic drugs (short for "targeted-immune therapy") combined with radiofrequency
ablation (RFA) and RFA alone in the treatment of recurrent hepatocellular carcinoma(HCC)
in 1-year recurrence-free survival (RFS) and overall survival (OS)
2. To evaluate the clinical value of systemic neoadjuvant therapy (i.e. immune checkpoint
inhibitors and targeted therapy) combined with RFA in the treatment of recurrent HCC, as
well as the safety and efficacy of this strategy.